Wellmarker Bio signs MOU with AZothBio, an AI-based drug development company on October 11, 2019. Through this agreement, Wellmarker Bio expects to commercialize its anticancer drug candidate by leveraging Azothbio’s AI platform.
Wellmarker Bio signs MOU with AZothBio, an AI-based drug development company on October 11, 2019. Through this agreement, Wellmarker Bio expects to commercialize its anticancer drug candidate by leveraging Azothbio’s AI platform.